INO Aug 2021 14.000 put

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

6.250.00 (0.00%)

As of 11:12AM EDT. Market open.

Motley Fool
Here's the Dr. Fauci Statement That Could Mean Good News for Inovio
Inovio Pharmaceuticals (NASDAQ: INO) was among the first to start clinical trials on a coronavirus vaccine candidate. The U.S. Food and Drug Administration (FDA) last fall placed one of Inovio's vaccine trials on a partial clinical hold, and the program fell behind. Now, Inovio's candidate is in phase 2.
Zacks
Do Options Traders Know Something About Inovio (INO) Stock We Don't?
Investors need to pay close attention to Inovio (INO) stock based on the movements in the options market lately.
Business Wire
INOVIO INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inovio Pharmaceuticals Inc. - INO
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into Inovio Pharmaceuticals Inc. (NasdaqGS: INO).